Licenses, Asset Acquisitions and Contingent Consideration (Tables)

3 Months Ended

Mar. 31, 2021

Business Combinations [Abstract]

Schedule of IPR&D Expense

The Company recorded the following IPR&D expense on the condensed consolidated statements of operations (in thousands):

	Three months ended March 31,
	2021		2020
Seralutinib	$	—	$	—
GB004	—		—
GB1275	—		—
Other preclinical programs	30		2,805
Total in process research and development	$	30	$	2,805